英科医疗(300677) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,471,788,445, a decrease of 50.48% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥236,207,795, down 77.79% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥182,176,188, a decline of 82.83% compared to the previous year[7]. - The basic earnings per share for Q3 2022 was ¥0.36, representing a decrease of 77.36% year-on-year[7]. - The company reported a significant decrease in operating income for the first nine months of 2022, totaling ¥5,212,259,481, down 61.81% year-on-year[12]. - Total operating revenue for the current period is $5.21 billion, a decrease of 61.7% from $13.65 billion in the previous period[36]. - Net profit for the current period is $632.88 million, a decline of 90.9% compared to $6.97 billion in the previous period[38]. - Total profit for the current period is $839.66 million, a decrease of 89.6% from $8.09 billion in the previous period[38]. Assets and Liabilities - Total assets at the end of Q3 2022 were ¥20,297,045,673, a decrease of 1.59% from the end of the previous year[7]. - The company’s total equity attributable to shareholders at the end of Q3 2022 was ¥15,912,191,683, a slight increase of 0.26% from the end of the previous year[7]. - The company's total current assets decreased to RMB 9.29 billion from RMB 10.76 billion, a decline of 13.7%[30]. - The company's total liabilities decreased to RMB 4.14 billion from RMB 4.50 billion, a reduction of 8.1%[32]. - The company's total equity increased to RMB 16.16 billion from RMB 16.12 billion, reflecting a growth of 0.2%[32]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥1,290,552,992, down 84.42% compared to the same period last year[7]. - Net cash flow from operating activities decreased by 84.42% to 1,290,552,992 from 8,282,856,582, mainly due to a decrease in cash received from sales[15]. - Cash flow from operating activities generated $1.29 billion, a decrease of 84.4% from $8.28 billion in the previous period[42]. - Cash inflows from financing activities totaled 1,020,593,466.00, compared to 575,045,674.00 in the previous period[45]. - Cash outflows from financing activities amounted to 1,457,247,972.00, an increase from 1,126,800,743.00 in the previous period[45]. - The net increase in cash and cash equivalents was 1,343,002,052.00, compared to 541,512,985.00 in the previous period[45]. Investments and Expenses - The company experienced a 1634.60% increase in investment income for the first nine months, amounting to ¥29,933,159[12]. - The company reported a 225.84% increase in fair value changes in investment income, totaling ¥61,711,328 for the first nine months[12]. - Operating expenses rose by 68.51% to 24,081,371 from 14,290,970, mainly due to increased donation expenses during the reporting period[15]. - Research and development expenses for the current period are $198.42 million, a reduction of 25% from $264.56 million in the previous period[36]. - Sales expenses decreased to $175.73 million, down 33.5% from $264.47 million in the previous period[36]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 86,877, with the top ten shareholders holding 35.06% of shares[16]. - Liu Fangyi, a major shareholder, holds 35.06% of shares, totaling 231,221,607[16]. - The company has allocated between RMB 250 million and RMB 500 million for share repurchase to implement employee stock ownership plans and/or equity incentives[26]. - The maximum repurchase price was set at RMB 34.38 per share, with the highest transaction price recorded at RMB 25.20 per share[26]. - The company has repurchased a total of 11,677,725 shares, accounting for 1.7706% of the total share capital, with a total transaction amount of approximately RMB 269 million[26]. Project Updates - The company terminated the high-end medical glove project with an annual production capacity of 40 billion units, as well as a cogeneration project in the Changlingqi New Port area[25]. - The company completed the registration of the restricted stock incentive plan on September 15, 2022, with 5,886,000 shares added to the restricted stock[24]. Miscellaneous - The impact of exchange rate changes on cash and cash equivalents was a significant decrease of 2,203.84% to 389,631,704 from -18,520,047[15]. - The company's third-quarter report was not audited[46].